MK-571 sodium
Based on 36 publication(s) in Google Scholar
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 115103-85-0
- Formula: C26H26ClN2NaO3S2
- Molecular Weight:537.07
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) MK-571 sodium
More- Nature. 2026 May;653(8115):933-941. [Abstract]
- Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]
- Cancer Res. 2026 May 27:10.1158/0008-5472.CAN-25-5172. [Abstract]
- Nat Commun. 2023 Sep 19;14(1):5709. [Abstract]
- Adv Sci (Weinh). 2025 Aug 4:e04680. [Abstract]
- Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
- Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]
- Food Res Int. 2026 Mar 31:228:118352. [Abstract]
- Biomed Pharmacother. 2020 Sep;129:110506. [Abstract]
- Biomed Pharmacother. 2018 Oct:106:1563-1569. [Abstract]
- Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]
- Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]
- Int J Nanomedicine. 2019 Nov 27;14:9217-9234. [Abstract]
- Pharmaceutics. 2024 May 29;16(6):731. [Abstract]
- Chem Biol Interact. 2026 Aug 1:436:112206. [Abstract]
- Commun Biol. 2024 May 23;7(1):621. [Abstract]
- CNS Neurosci Ther. 2023 Jan;29(1):445-457. [Abstract]
- Int J Mol Sci. 2026 Mar 13;27(6):2646. [Abstract]
- J Drug Deliv Sci Technol. 2025 May.
- Eur J Pharm Sci. 2023 May 1:184:106414. [Abstract]
- Toxicology. 2025 Jun 3:154210. [Abstract]
- Drug Metab Dispos. 2025 Nov;53(11):100172. [Abstract]
- Brain Res Bull. 2022 Oct 15:189:69-79. [Abstract]
- Regul Toxicol Pharmacol. 2019 Nov:108:104449. [Abstract]
- Viruses. 2019 Apr 24;11(4):378. [Abstract]
- Cancer Res Commun. 2024 Apr 9;4(4):1024-1040. [Abstract]
- J Pharm Biomed Anal. 2020 Sep 10;189:113441. [Abstract]
- 3 Biotech. 2025 Apr;15(4):72. [Abstract]
- Toxicol Lett. 2020 Jul 1;327:9-18. [Abstract]
- J Appl Toxicol. 2024 Nov;44(11):1725-1741. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):609-617. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):279-289. [Abstract]
- Pharmacol Res Perspect. 2022 Feb;10(1):e00928. [Abstract]
- Cytotechnology. 2026 Jun;78(3):104. [Abstract]
- Xenobiotica. 2020 Mar;50(3):354-362. [Abstract]
- Eberhard Karls Universität Tübingen. 2022 Feb.
Customer Validation & Images
-
IF
-
WB
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
All Leukotriene Receptor Isoforms
More
Biological Activity
|
LTD4 0.22±0.15 nM (Ki, In guinea pig lung) |
LTD4 2.1±1.8 nM (Ki, In human lung) |
LTD4 10.5 (pA2) |
LTE4 10.4 (pA2) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 2008 | IC50 |
7.57 μM
Compound: MK-571
|
Inhibition of human MRP1 in human 2008 cells
Inhibition of human MRP1 in human 2008 cells
|
[PMID: 18707884] |
| MDCK-II | IC50 |
>30 μM
Compound: MK571
|
Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux
Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux
|
[PMID: 26774038] |
| MDCK-II | IC50 |
20.7 μM
Compound: MK-571
|
Inhibition of human MRP2 expressed in dog MDCK2 cells
Inhibition of human MRP2 expressed in dog MDCK2 cells
|
[PMID: 18707884] |
MK571 sodium (15 μM, 1 h) markedly suppresses constitutive and Ag-stimulated S1P secretion from RBL-2H3 cells and mast cells, and inhibits Fluo-3 efflux[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RBL-2H3 cells, human LAD2 mast cells
-
Concentration:15 μM
-
Incubation Time:1 h
-
Result:Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.
MK-571 sodium (0-1 mg/kg, orally, once) blocks LTD4- and Ascaris-induced bronchoconstriction in conscious squirrel monkeys[1].
MK-571 sodium (0-25 mg/kg, orally, daily, for 2 more weeks) shows reversal of hypoxic pulmonary hypertension (PH), and protects mice from hypoxic PH[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3 μg/kg methysergide, 5 min before antigen chdlenge)[1]
-
Dosage:0.5, 0.15, and 0.05 mg/kg
-
Administration:Orally, once, 1 or 4 h before challenge
-
Result:Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED50 values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED50 of 0.068 (95% CI, 0.83-0.14) mg/kg.
-
Animal Model:Csnscisus squirrel msnkeys[1]
-
Dosage:0.1, 0.5, and 1 mg/kg
-
Administration:Orally, once, 2 h prior to challenge with Ascaris antigen
-
Result:Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in RL and decreases in Cdyn at 1 mg/kg.
-
Animal Model:FVB (Friend virus B-type) mice (Mrp4–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O2) in a ventilated chamber for 28 days)[2]
-
Dosage:0, 5, and 25 mg/kg
-
Administration:Orally, daily, for 2 more weeks, maintain in hypoxic conditions
-
Result:Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.
Chemical Information
-
CAS No. 115103-85-0
-
Appearance Solid
-
Molecular Weight 537.07
-
Formula C26H26ClN2NaO3S2
-
Color Light yellow to yellow
-
SMILES
O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O
-
Synonyms
L-660711 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (36)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 May;653(8115):933-941. PMID: 41851454 -
Cell
2023 Dec 7;186(25):5500-5516.e21. PMID: 38016470
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]
Survival curves for mice subjected to SD (SR means 48 h of recovery after SD) with oral administration of MK-571 sodium (0.1 mg/mL) (n = 10) in the drinking water compared with water controls (n = 10). The results showed that MK-571 sodium protected against SD-induced mortality.
-
Cancer Res
Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. [Abstract]2026 May 27:10.1158/0008-5472.CAN-25-5172. PMID: 42200804 -
Nat Commun
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]2023 Sep 19;14(1):5709. PMID: 37726279 -
Adv Sci (Weinh)
Fusidic Acid Reverses Chemoresistance in Breast Cancer via Targeting DDX6 to Downregulate GSK-3β/β-Catenin Signaling. [Abstract]2025 Aug 4:e04680. PMID: 40757496 -
Sci Adv
2024 Dec 13;10(50):eadq4274. PMID: 39661665
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
Cells were treated with the ABCC1 inhibitor MK-571 sodium (10 μM) and MRTX849 for 3 days, followed by CCK-8 assays. The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 sodium for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
-
Free Radic Biol Med
Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]
HT1080 and HUH7 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).
-
Food Res Int
Hydroxypropyl-β-cyclodextrin as a co-delivery vehicle for synergistically enhancing fucoxanthin oral bioavailability through dual regulation of SR-B1 and ABCB1 transporters. [Abstract]2026 Mar 31:228:118352. PMID: 41703824 -
Biomed Pharmacother
Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. [Abstract]2020 Sep;129:110506. PMID: 32768979
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep;129:110506. [Abstract]
MK-571 (50 μM, 10 min) increased the accumulation of [3H]-MVC in BeWo cells.
-
Biomed Pharmacother
Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model. [Abstract]2018 Oct:106:1563-1569. PMID: 30119231 -
Cell Death Discov
Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys. [Abstract]2024 Aug 14;10(1):364. PMID: 39143064
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]
MK-571 (5 μM, 30 min) increased the fluorescence intensity of DOX-inducible CD10+ PTEC CMFDA metabolites.
-
Arch Toxicol
In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. [Abstract]2020 Nov;94(11):3799-3817. PMID: 32915249
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]
The MRP1 inhibitor MK-571 sodium (50 µM; 1 h) decreased A–B MeHg transport in MDCKII-MRP1 cells.
-
Int J Nanomedicine
The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]2019 Nov 27;14:9217-9234. PMID: 31819426 -
Pharmaceutics
Study on the Effect of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Baicalin in Cells Based on MRP2, MRP3, and BCRP Efflux Transporters. [Abstract]2024 May 29;16(6):731. PMID: 38931853 -
Chem Biol Interact
A microfluidic human blood-brain barrier model reveals neurovascular toxicity and barrier disruption induced by E-cigarette additives. [Abstract]2026 Aug 1:436:112206. PMID: 42285244 -
Commun Biol
2024 May 23;7(1):621. PMID: 38783088 -
CNS Neurosci Ther
2023 Jan;29(1):445-457. PMID: 36253925 -
Int J Mol Sci
LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]2026 Mar 13;27(6):2646. PMID: 41898509 -
-
Eur J Pharm Sci
Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. [Abstract]2023 May 1:184:106414. PMID: 36858275 -
Toxicology
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]2025 Jun 3:154210. PMID: 40473197
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]
MK-571 (5 μM, 1 h) dilates the bile canalicular area in HepaRG cells.
MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]
MK-571 (5 μM, 6 h) reduced the expression of NTCP, BSEP, and MRP3 in HepaRG cells.
-
Drug Metab Dispos
Activation of pregnane X receptor-organic anion transporting polypeptide 1a/b /P-glycoprotein/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. [Abstract]2025 Nov;53(11):100172. PMID: 41106060 -
Brain Res Bull
Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters. [Abstract]2022 Oct 15:189:69-79. PMID: 35981629 -
Regul Toxicol Pharmacol
2019 Nov:108:104449. PMID: 31449916 -
Viruses
Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. [Abstract]2019 Apr 24;11(4):378. PMID: 31022917 -
Cancer Res Commun
Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]2024 Apr 9;4(4):1024-1040. PMID: 38592451 -
J Pharm Biomed Anal
Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS. [Abstract]2020 Sep 10;189:113441. PMID: 32615340 -
3 Biotech
Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]2025 Apr;15(4):72. PMID: 40060290 -
Toxicol Lett
SOD2 promotes the expression of ABCC2 through lncRNA CLCA3p and improves the detoxification capability of liver cells. [Abstract]2020 Jul 1;327:9-18. PMID: 32201199 -
J Appl Toxicol
Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters. [Abstract]2024 Nov;44(11):1725-1741. PMID: 39030772 -
Eur J Drug Metab Pharmacokinet
The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier. [Abstract]2024 Sep;49(5):609-617. PMID: 38963639 -
Eur J Drug Metab Pharmacokinet
Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier. [Abstract]2022 Mar;47(2):279-289. PMID: 35112329 -
Pharmacol Res Perspect
The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by interacting with UDP-glucuronosyltransferases and efflux transport proteins. [Abstract]2022 Feb;10(1):e00928. PMID: 35148019 -
Cytotechnology
Exploring the laxative effects of emodin on constipation through chloride channel activation. [Abstract]2026 Jun;78(3):104. PMID: 42083655 -
Xenobiotica
The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. [Abstract]2020 Mar;50(3):354-362. PMID: 31132291 -
Solvent & Solubility
DMSO : 50 mg/mL (93.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. [Content Brief]
[2]. Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97. [Content Brief]
[3]. Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8620 mL | 9.3098 mL | 18.6195 mL | 46.5489 mL |
| 5 mM | 0.3724 mL | 1.8620 mL | 3.7239 mL | 9.3098 mL | |
| 10 mM | 0.1862 mL | 0.9310 mL | 1.8620 mL | 4.6549 mL | |
| 15 mM | 0.1241 mL | 0.6207 mL | 1.2413 mL | 3.1033 mL | |
| 20 mM | 0.0931 mL | 0.4655 mL | 0.9310 mL | 2.3274 mL | |
| 25 mM | 0.0745 mL | 0.3724 mL | 0.7448 mL | 1.8620 mL | |
| 30 mM | 0.0621 mL | 0.3103 mL | 0.6207 mL | 1.5516 mL | |
| 40 mM | 0.0465 mL | 0.2327 mL | 0.4655 mL | 1.1637 mL | |
| 50 mM | 0.0372 mL | 0.1862 mL | 0.3724 mL | 0.9310 mL | |
| 60 mM | 0.0310 mL | 0.1552 mL | 0.3103 mL | 0.7758 mL | |
| 80 mM | 0.0233 mL | 0.1164 mL | 0.2327 mL | 0.5819 mL |
MK-571 sodium Related Classifications
HY-19989A Related Classifications
Powered by Bioz